Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Anas Almoghrabi, Estefania Flores, Obaie Mzaik, Chimezie Mbachi, Bashar Attar and Melchor Demetria
A substantial proportion of patients with Crohn’s Disease (CD) do not respond to the currently available medications with potential long-term consequences. Consequently, alternative safer therapies are being studied, such as Fecal Microbiota Transplantation (FMT). The Food and Drug Administration (FDA) approved the use of FMT for recurrent Clostridium difficile (C. diff) but has tighter restrictions for Inflammatory Bowel Disease (IBD). Those patients can only get a fecal transplant in a medical setting if they are participating in a clinical trial. A handful of case reports have shown the effectiveness of self-administered home fecal transplant in recurrent C. difficile, and the efficacy of FMT, under monitored environment, in refractory CD unresponsive to current conventional therapy. However, no reported cases showing the efficacy of self-administered home fecal transplant in patients with fistulizing CD. This is the first case report showing the efficacy of self-administered home fecal transplant as a single agent in the management of Crohn’s pancolitis with perianal fistulae.